Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

被引：6
|
作者：
Marascio, Nadia [1 ]
Mazzitelli, Maria [2 ]
Pavia, Grazia [1 ]
Giancotti, Aida [1 ]
Barreca, Giorgio Settimo [1 ]
Costa, Chiara [2 ]
Pisani, Vincenzo [2 ]
Greco, Giuseppe [2 ]
Serapide, Francesca [2 ]
Trecarichi, Enrico Maria [2 ]
Casalinuovo, Francesco [3 ]
Liberto, Maria Carla [1 ]
Matera, Giovanni [1 ]
Torti, Carlo [2 ]
机构：
[1] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Unit Clin Microbiol, I-88100 Catanzaro, Italy
[2] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Unit Infect & Trop Dis, I-88100 Catanzaro, Italy
[3] Inst Expt Vet Med Southern Italy, I-88100 Catanzaro, Italy
来源：
CELLS | 2019年 / 8卷 / 05期
关键词：
pediatric patients; Hepatitis C virus 4; sofosbuvir; ledipasvir; RESISTANCE-ASSOCIATED SUBSTITUTIONS; TRANSMISSION; SOFOSBUVIR;
D O I：
10.3390/cells8050416
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] Treatment of adolescents genotype 4 chronic HCV infected patients with Ledipasvir/Sofosbuvir combination: A real world experience
    Khayat, H. E.
    Kamal, I.
    El-Sayed, M. H.
    Ayoub, H.
    Shabrawy, M. E.
    Rizk, A.
    Yehia, R.
    Maher, M.
    Fouad, Y.
    Attia, D.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 68 : S327 - S327
  • [2] Ledipasvir/Sofosbuvir in Egyptian Patients with Chronic Genotype 4 HCV Infection
    Shiha, Gamal
    Waked, Imam
    Soliman, Reham
    Abdel-Razek, Wael
    Hassany, Mohamed
    Omar, Rabab F.
    Samir, Waleed
    Zakareya, Talaat
    Hammad, Radi
    Musa, Sherief
    Kersey, Kathryn
    Lu, Sophia
    Massetto, Benedetta
    Brainard, Diana M.
    McHutchison, John G.
    Doss, Wahid H.
    Esmat, Gamal E.
    [J]. HEPATOLOGY, 2016, 64 : 436A - 437A
  • [3] Ledipasvir/Sofosbuvir in the Treatment of Japanese Patients with Chronic HCV Genotype 2 Infection
    Asahina, Yasuhiro
    Itoh, Yoshito
    Ueno, Yoshiyuki
    Matsuzaki, Yasushi
    Takikawa, Yasuhiro
    Yatsuhashi, Hiroshi
    Genda, Takuya
    Ikeda, Fusao
    Matsuda, Takuma
    Huang, K. C.
    Massetto, Benedetta
    Osinusi, Anu O.
    Brainard, Diana M.
    McHutchison, John G.
    Kawada, Norifumi
    Enomoto, Nobuyuki
    [J]. HEPATOLOGY, 2017, 66 : 638A - 638A
  • [4] LONG-TERM OUTCOMES OF LEDIPASVIR/SOFOSBUVIR (LDV/ SOF) FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTED (HCV) GENOTYPE 1 PATIENTS IN THE UK
    Guerra, I
    Marie, L.
    Cure, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A675 - A675
  • [5] Sofosbuvir and ledipasvir for HIV/HCV co-infected patients
    Rosenthal, Elana S.
    Kottilil, Shyam
    Polis, Michael A.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (05) : 743 - 749
  • [6] LEDIPASVIR/SOFOSBUVIR TREATMENT RESULTS IN HIGH SVR RATES IN PATIENTS WITH CHRONIC GENOTYPE 4 AND 5 HCV INFECTION
    Abergel, A.
    Loustaud-Ratti, V.
    Metivier, S.
    Jiang, D.
    Kersey, K.
    Knox, S. J.
    Pang, P. S.
    Samuel, D.
    Asselah, T.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S219 - S220
  • [7] On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir
    Kowdley, Kris V.
    Nelson, David R.
    Lalezari, Jacob P.
    Box, Terry
    Gitlin, Norman
    Poleynard, Gary
    Rabinovitz, Mordechai
    Ravendhran, Natarajan
    Sheikh, Aasim M.
    Siddique, Asma
    Bhore, Rafia
    Noviello, Stephanie
    Rana, Khurram
    [J]. LIVER INTERNATIONAL, 2016, 36 (11) : 1611 - 1618
  • [8] Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients
    Abdelaty, Lamiaa N.
    Elnaggar, Ahmed A.
    Said, Amira A.
    Hussein, Raghda R. S.
    [J]. CURRENT DRUG SAFETY, 2020, 15 (01) : 53 - 60
  • [9] Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection
    Mangia, A.
    Sarli, R.
    Gamberini, R.
    Piga, A.
    Cenderello, G.
    Piazzolla, V.
    Santoro, R.
    Caruso, V.
    Quarta, A.
    Ganga, R.
    Copetti, M.
    Forni, G.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (04) : 424 - 431
  • [10] Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes
    Vo-Quang, Erwan
    Soulier, Alexandre
    Ndebi, Melissa
    Rodriguez, Christophe
    Chevaliez, Stephane
    Leroy, Vincent
    Fourati, Slim
    Pawlotsky, Jean-Michel
    [J]. HEPATOLOGY, 2023, 78 (02) : 607 - 620
12345